NCT03892993
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Thyroid Gland Medullary Carcinoma
Explore clinical trials studying Thyroid Gland Medullary Carcinoma. Study availability and eligibility vary by location and protocol.
17 public trials
1 recruiting study
Thyroid Gland Medullary Carcinoma trial results
Not yet recruiting
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
NCT07612293
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
Active, not recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592
- Conditions
- Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim Anaheim, California, United States
Active, not recruiting
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT07118176
- Conditions
- Adenocarcinoma, Adnexal Diseases, Adrenal Gland Diseases, +127 more
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
Active, not recruiting
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT04759911
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Carcinoma, +25 more
- Locations
-
- Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
- University of Michigan Health Systems Ann Arbor, Michigan, United States
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
NCT02293954
- Conditions
- Adenocarcinoma, Bile Duct Diseases, Bile Duct Neoplasms, +59 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT00655655
- Conditions
- Adenocarcinoma, Adenoma, Adenoma, Islet Cell, +70 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
NCT02592356
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +15 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
NCT01709435
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +30 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Children's Hospital of Orange County Orange, California, United States
- UCSF Medical Center-Parnassus San Francisco, California, United States
- UCSF Medical Center-Mission Bay San Francisco, California, United States
Completed
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
NCT00519896
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +26 more
- Locations
-
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States